Protech Continues Rapid Expansion with Opening of Two New Locations Focused on Respiratory Therapy Products and Services
16 March 2021 - 11:00PM
Protech Home Medical Corp. (“
Protech” or the
“
Company”) (TSXV:PTQ; OTCQX:PTQQF), a U.S. based
leader in the home medical equipment industry, focused on
end-to-end respiratory care, is pleased to announce that it has
accelerated its organic growth initiatives with the opening of a
new location in Daytona Beach, Florida and Concord, New Hampshire.
Location Details
The Company has opened a new location in Daytona
Beach, Florida, which is expected to boost its ongoing early
expansion efforts in the State. The new location in Daytona Beach
will have a heavily respiratory weighted product mix which is
expected to help the Company reach surrounding areas at an
accelerated pace, as well as cut down on logistical costs. On
February 2, 2021, the Company acquired Mayhugh’s Medical Equipment
(“MME”) in Jacksonville, Florida to begin building
a foundation poised for growth in the new State. MME added 10,000
active patients to Protech’s patient population, and the Company is
well into the integration process. The Company’s plan continues to
be to utilize its existing highly scalable infrastructure to grow
the patient base and anticipates adding additional locations either
through organic opportunities such as Daytona Beach or through
inorganic opportunities that may present themselves.
The Company has also opened a new location in
Concord, New Hampshire. Concord is the Capital of New Hampshire and
allows Protech to further penetrate the State and surrounding
regions. The location will have a heavily weighted respiratory
product mix and leverage the infrastructure on the ground in New
Hampshire to quickly scale.
Protech expects to derive strong revenue
synergies from the initiative of opening new locations organically
and will continue to implement its high touch service model in both
new locations.
The Company is pleased to share the following
current financial and operating metrics. Please note these metrics
do not include potential future acquisitions or ongoing organic
growth initiatives:
- Run-Rate Revenue of USD$100-$105
million
- 120,000 current active
patients
- 17,000 unique referrals
- 51 locations across 11 U.S.
States
Management Commentary
“With the addition of new locations in Florida
and New Hampshire we continue our aggressive path of scaling our
business. We believe coupling organic initiatives such as
strategically opening new locations, combined with our robust
acquisition plans has significantly widened our aperture of
opportunity for our business,” said Greg Crawford, Chairman and CEO
of Protech. “Our patient centric model leveraging our
interconnected healthcare platform is providing us much opportunity
to gain market share and this is just the beginning for us. We have
additional plans to increase our footprint in current markets as
well as adding new markets in our pursuit of becoming a leading
national provider of respiratory therapy products and services in
the home. Moreover, we must ensure our brand aligns with our
mission, ensuring we are building strong brand equity to further
accelerate organic growth opportunities, and we expect to have more
to share on this front in the near future. Finally, we are
incredibly excited about our deep pipeline of potential acquisition
targets, which we expect to be very busy in the near term and look
forward to updating shareholders when appropriate.”
ABOUT PROTECH HOME MEDICAL
CORP.
The Company provides in-home monitoring and
disease management services including end-to-end respiratory
solutions for patients in the United States healthcare market. It
seeks to continue to expand its offerings to include the management
of several chronic disease states focusing on patients with heart
or pulmonary disease, sleep disorders, reduced mobility and other
chronic health conditions. The primary business objective of the
Company is to create shareholder value by offering a broader range
of services to patients in need of in-home monitoring and chronic
disease management. The Company’s organic growth strategy is to
increase annual revenue per patient by offering multiple services
to the same patient, consolidating the patient’s services and
making life easier for the patient.
Forward-Looking Statements
Certain statements contained in this press
release constitute "forward-looking information" as such term is
defined in applicable Canadian securities legislation. The words
"may", "would", "could", "should", "potential", "will", "seek",
"intend", "plan", "anticipate", "believe", "estimate", "expect" and
similar expressions as they relate to the Company, including:
the Company expecting its new Daytona Beach location to boost its
ongoing early expansion efforts in Florida and helping the Company
reach surrounding areas at an accelerated pace, as well as cut down
on logistical costs; the Company anticipating to add additional
locations either through organic opportunities or through inorganic
opportunities; the Company expecting to derive strong revenue
synergies from new locations organically; the Company’s plans to
increase its footprint in current markets as well as adding new
markets; the Company expecting to have further news on organic
growth opportunities in the near future; and the Company expecting
to be busy with new acquisitions in the near term; are intended to
identify forward-looking information. All statements other than
statements of historical fact may be forward-looking
information. Such statements reflect the Company's current views
and intentions with respect to future events, and current
information available to the Company, and are subject to certain
risks, uncertainties and assumptions, including: the Company
successfully identified, negotiating and completing additional
acquisitions, including accretive acquisitions. Many factors could
cause the actual results, performance or achievements that may be
expressed or implied by such forward-looking information to vary
from those described herein should one or more of these risks or
uncertainties materialize. Examples of such risk factors include,
without limitation: credit; market (including equity, commodity,
foreign exchange and interest rate); liquidity; operational
(including technology and infrastructure); reputational;
insurance; strategic; regulatory; legal; environmental; capital
adequacy; the general business and economic conditions in the
regions in which the Company operates; the ability of the Company
to execute on key priorities, including the successful completion
of acquisitions, business retention, and strategic plans and to
attract, develop and retain key executives; difficulty
integrating newly acquired businesses; the ability to implement
business strategies and pursue business opportunities; low profit
market segments; disruptions in or attacks (including
cyber-attacks) on the Company's information technology, internet,
network access or other voice or data communications systems or
services; the evolution of various types of fraud or other
criminal behavior to which the Company is exposed; the failure
of third parties to comply with their obligations to the Company
or its affiliates; the impact of new and changes to, or
application of, current laws and regulations; decline of
reimbursement rates; dependence on few payors; possible new drug
discoveries; a novel business model; dependence on key
suppliers; granting of permits and licenses in a highly regulated
business; the overall difficult litigation environment,
including in the U.S.; increased competition; changes in foreign
currency rates; increased funding costs and market volatility
due to market illiquidity and competition for funding; the
availability of funds and resources to pursue operations;
critical accounting estimates and changes to accounting standards,
policies, and methods used by the Company; the occurrence of
natural and unnatural catastrophic events and claims resulting
from such events; and risks related to COVID-19 including various
recommendations, orders and measures of governmental
authorities to try to limit the pandemic, including travel
restrictions, border closures, non-essential business closures,
quarantines, self-isolations, shelters-in-place and social
distancing, disruptions to markets, economic activity,
financing, supply chains and sales channels, and a deterioration
of general economic conditions including a possible national
or global recession; as well as those risk factors discussed or
referred to in the Company’s disclosure documents filed with
the securities regulatory authorities in certain provinces of
Canada and available at www.sedar.com. Should any factor affect
the Company in an unexpected manner, or should assumptions
underlying the forward-looking information prove incorrect, the
actual results or events may differ materially from the results
or events predicted. Any such forward-looking information is
expressly qualified in its entirety by this cautionary
statement. Moreover, the Company does not assume responsibility
for the accuracy or completeness of such forward-looking
information. The forward-looking information included in this
press release is made as of the date of this press release and
the Company undertakes no obligation to publicly update or revise
any forward-looking information, other than as required by
applicable law.
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
For further information please visit our website
at www.protechhomemedical.com, or contact:
Cole StevensVP of Corporate Development Protech
Home Medical Corp.859-300-6455cole.stevens@myphm.com
Gregory CrawfordChief Executive OfficerProtech
Home Medical Corp.859-300-6455investorinfo@myphm.com
Protech Home Medical (TSXV:PTQ)
Historical Stock Chart
From Dec 2024 to Jan 2025
Protech Home Medical (TSXV:PTQ)
Historical Stock Chart
From Jan 2024 to Jan 2025